Kathryn E. Reinicke, Ph.D.
Affiliations: | 2007 | Case Western Reserve University, Cleveland Heights, OH, United States |
Area:
Biochemistry, Cell BiologyGoogle:
"Kathryn Reinicke"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| David A. Boothman | grad student | 2007 | Case Western | |
| (Prodrug development and the role of reactive oxygen species in beta-lapachone-mediated cell death.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jayaraman S, Hou X, Kuffel MJ, et al. (2020) Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research : Bcr. 22: 51 |
| Reid JM, Goetz MP, Buhrow SA, et al. (2014) Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparative in vivo activity studies Cancer Chemotherapy and Pharmacology. 74: 1271-1278 |
| Cao L, Li LS, Spruell C, et al. (2014) Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxidants & Redox Signaling. 21: 237-50 |
| Bey EA, Reinicke KE, Srougi MC, et al. (2013) Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Molecular Cancer Therapeutics. 12: 2110-2120 |
| Goetz M, Kuffel M, Reinicke K, et al. (2013) Abstract P5-09-08: A comparison of the non-genomic effects of endoxifen and tamoxifen in aromatase inhibitor resistant breast cancer: Differential effects on the estrogen receptor co-regulator SRC3 (AIB1) and identification of PKC and PI3K as endoxifen substrates Cancer Research. 73 |
| Safgren SL, Buhrow SA, Walden C, et al. (2012) Abstract 3781: Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparativein vivoactivity studies Cancer Research. 72: 3781-3781 |
| Reinicke KE, Hou X, Goetz MP, et al. (2011) Abstract 2283: Endoxifen exhibits potentin vitroandin vivoantitumor activity in ER+/HER2+ breast cancer and tamoxifen refractory tumors Cancer Research. 71: 2283-2283 |
| Goetz M, Hou X, Suman V, et al. (2011) PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. Cancer Research. 71 |
| Reinicke KE, Kuffel MJ, Goetz MP, et al. (2010) Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemotherapy and Pharmacology. 66: 575-83 |
| Goetz M, Reinicke K, Reid J, et al. (2009) Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer. Cancer Research. 69: 2006-2006 |